Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for generalized pustular psoriasis
ChiCTR2400083906Phase 3Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of secukinumab in generalized pustular psoriasis (GPP) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Generalized Pustular Psoriasis Physician Global Assessment / Pustular score. Started May 2024; status: recruiting.
02
Drugs
secukinumab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on ChiCTR2400083906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083906.